The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Randomized Trial of an Inhibitor of Formation of Advanced Glycation End Products in Diabetic Nephropathy
Abstract
Background/Aims: Pimagedine inhibits the formation of advanced glycation end products and slows the progression of diabetic complications in experimental models. This study was undertaken to determine if pimagedine ameliorates nephropathy in type 1 (insulin-dependent) diabetes mellitus. Methods: This was a randomized, double-masked, placebo-controlled study performed in 690 patients with type 1 diabetes mellitus, nephropathy, and retinopathy. The patients received twice daily dosing with placebo, pimagedine 150 mg, or pimagedine 300 mg for 2–4 years. The primary end point was the time to doubling of serum creatinine; the secondary end points included evaluations of proteinuria, kidney function, and retinopathy. Results: Serum creatinine doubled in 26% (61/236) of the placebo-treated patients and in 20% (91/454) of those who received pimagedine (p = 0.099). The estimated glomerular filtration rate decreased more slowly in the pimagedine-treated patients with a 36-month decrease from baseline of 6.26 ml/min/1.73 m 2 as compared with 9.80 ml/min/1.73 m 2 in the placebo-treated patients (p = 0.05), and pimagedine reduced the 24-hour total urinary proteinuria. (The mean reduction from baseline at month 36 was 732 mg/24 h at the low dose and 329 mg/24 h at the high dose as compared with 35 mg/24 h in the placebo group; p ≤ 0.001.) Fewer pimagedine-treated patients with baseline and end point evaluations (31/324; 10%) as compared with those receiving placebo (16%; 28/179) experienced a three-step or greater progression of the retinopathy (Early Treatment of Diabetic Retinopathy Study) score (p = 0.030). Three patients receiving high-dose pimagedine but none receiving low-dose treatment developed glomerulonephritis. Conclusions: While this study did not demonstrate a statistically significant beneficial effect of pimagedine on the progression of overt nephropathy resulting from type 1 diabetes, it is noteworthy in providing the first clinical proof of the concept that inhibiting advanced glycation end product formation can result in a clinically important attenuation of the serious complications of type 1 diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · cited 1×
“In man, the risk of renal disease progression is highly associated with the level of proteinuria: in recently reported trials of kidney disease progression, the groups with reductions in proteinuria had slower rates of decline [ , ,”
BackgroundThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Doqi, K. (2002) · American Journal of Kidney Diseases · Cited by 1,285
Agodoa, L. Y. (2001) · JAMA · doi:10.1001/jama.285.21.2719 · Cited by 944
Keane, W. F., & Eknoyan, G. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70442-7 · Cited by 591
Tobacco smoke is a source of toxic reactive glycation products
Cerami, C., Founds, H., Nicholl, I., Mitsuhashi, T., Giordano, D., Vanpatten, S., Lee, A., Al-Abed, Y., Vlassara, H., Bucala, R., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13915 · Cited by 549
Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats.
Vlassara, H., Striker, L. J., Teichberg, S., Fuh, H., Li, Y. M., & Steffes, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11704 · Cited by 462
Cited by
Cheung, N., Mitchell, P., & Wong, T. Y. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62124-3 · Cited by 3,288
Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261
Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness
Zieman, S. J., Melenovsky, V., & Kass, D. A. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000160548.78317.29 · Cited by 1,854
Diabetic nephropathy: diagnosis, prevention, and treatment
Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., & Zelmanovitz, T. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.164 · Cited by 1,839
Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss
Lee, R., Wong, T. Y., & Sabanayagam, C. (2015) · Eye and Vision · doi:10.1186/s40662-015-0026-2 · Cited by 1,569
Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Diabetes and mitochondrial function: Role of hyperglycemia and oxidative stress
Rolo, A. P., & Palmeira, C. M. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.01.003 · Cited by 1,007
“Pimagedine, which inhibits AGEs formation in experimental models, did not demonstrate a statistically significant beneficial effect on the progression of nephropathy resulting from type 1 diabetes (Bolton et al., 2004).”
BackgroundThe Role of Advanced Glycation End Products in Progression and Complications of Diabetes
Goh, S.-Y., & Cooper, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1817 · Cited by 987
Ramasamy, R., Vannucci, S. J., Yan, S. S. D., Herold, K., Yan, S. F., & Schmidt, A. M. (2005) · Glycobiology · doi:10.1093/glycob/cwi053 · Cited by 834
Diabetic neuropathy: Mechanisms to management
Edwards, J. L., Vincent, A. M., Cheng, H. T., & Feldman, E. L. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.05.005 · Cited by 790
Klaassen, I., Van Noorden, C. J. F., & Schlingemann, R. O. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.02.001 · Cited by 722
Gasotransmitters in cancer: from pathophysiology to experimental therapy
Szabo, C. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.1 · Cited by 717
Diabetes and advanced glycation endproducts
Vlassara, H., & Palace, M. R. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.00932.x · Cited by 697
Negre‐Salvayre, A., Coatrieux, C., Ingueneau, C., & Salvayre, R. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707395 · Cited by 641
Schalkwijk, C. G., & Stehouwer, C. D. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00001.2019 · Cited by 622
Diabetic nephropathy – complications and treatment
Lim, A. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s40172 · Cited by 583
Receptor for AGE (RAGE): Signaling mechanisms in the pathogenesis of diabetes and its complications
Ramasamy, R., Yan, S. F., & Schmidt, A. M. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06320.x · Cited by 521
Diabetic Microvascular Disease: An Endocrine Society Scientific Statement
Barrett, E. J., Liu, Z., Khamaisi, M., King, G. L., Klein, R., Klein, B. E. K., Hughes, T. M., Craft, S., Freedman, B. I., Bowden, D. W., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01922 · Cited by 515
Self-citationDoes accumulation of advanced glycation end products contribute to the aging phenotype?
Semba, R. D., Nicklett, E. J., & Ferrucci, L. (2010) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glq074 · Cited by 490
Qi, W., Keenan, H. A., Li, Q., Ishikado, A., Kannt, A., Sadowski, T., Yorek, M. A., Wu, I.-H., Lockhart, S., Coppey, L. J., et al. (2017) · Nature Medicine · doi:10.1038/nm.4328 · Cited by 479
Genuth, S., Sun, W., Cleary, P., Sell, D. R., Dahms, W., Malone, J., Sivitz, W., Monnier, V. M., & for the DCCT Skin Collagen Ancillary Study Group (2005) · Diabetes · doi:10.2337/diabetes.54.11.3103 · Cited by 427
Ashraf, J. M., Ansari, M. A., Khan, H. M., Alzohairy, M. A., & Choi, I. (2016) · Scientific Reports · doi:10.1038/srep20414 · Cited by 404
Advanced glycation end products and the kidney
Bohlender, J. M., Franke, S., Stein, G., & Wolf, G. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00398.2004 · Cited by 387
Vascular Aging: A Tale of EVA and ADAM in Cardiovascular Risk Assessment and Prevention
Nilsson, P. M., Boutouyrie, P., & Laurent, S. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.129114 · Cited by 380
AGE, RAGE, and ROS in Diabetic Nephropathy
Tan, A. L. Y., Forbes, J. M., & Cooper, M. E. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.01.006 · Cited by 368
Byun, K., Yoo, Y., Son, M., Lee, J., Jeong, G.-B., Park, Y. M., Salekdeh, G. H., & Lee, B. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.030 · Cited by 357
“Aminoguanidine was the first AGEs inhibitor found to inhibit the formation of AGEs, and was also reported to effectively reduce the pathologic effects of the nephropathy and vascular complications associated with AGEs in diabetes (Bolton et al., 2004; Brownlee et al., 1986; Freedman et al., 1999).”
Basta, G. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.07.025 · Cited by 357
Rosca, M. G., Mustata, T. G., Kinter, M. T., Ozdemir, A. M., Kern, T. S., Szweda, L. I., Brownlee, M., Monnier, V. M., & Weiss, M. F. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00415.2004 · Cited by 354
Role of advanced glycation end products in cardiovascular disease
Hegab, Z. (2012) · World Journal of Cardiology · doi:10.4330/wjc.v4.i4.90 · Cited by 354
Oxidative stress in early diabetic nephropathy: fueling the fire
Singh, D. K., Winocour, P., & Farrington, K. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.212 · Cited by 353
The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases
Maessen, D. E. M., Stehouwer, C. D. A., & Schalkwijk, C. G. (2015) · Clinical Science · doi:10.1042/cs20140683 · Cited by 334
Diabetes and Advanced Glycoxidation End Products
Huebschmann, A. G., Regensteiner, J. G., Vlassara, H., & Reusch, J. E. B. (2006) · Diabetes Care · doi:10.2337/dc05-2096 · Cited by 330
Fishman, S. L., Sonmez, H., Basman, C., Singh, V., & Poretsky, L. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0060-3 · Cited by 330
Inhibition of advanced glycation endproduct formation by foodstuffs
Wu, C.-H., Huang, S.-M., Lin, J.-A., & Yen, G.-C. (2011) · Food & Function · doi:10.1039/c1fo10026b · Cited by 328
Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets
Dewanjee, S., Das, S., Das, A. K., Bhattacharjee, N., Dihingia, A., Dua, T. K., Kalita, J., & Manna, P. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.034 · Cited by 300
Yamagishi, S.-I. (2011) · Experimental Gerontology · doi:10.1016/j.exger.2010.11.007 · Cited by 302
Oxidative stress and diabetic retinopathy: Pathophysiological mechanisms and treatment perspectives
Madsen-Bouterse, S. A., & Kowluru, R. A. (2008) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9090-4 · Cited by 302
Diabetic nephropathy: diagnosis and treatment
Fineberg, D., Jandeleit-Dahm, K. A. M., & Cooper, M. E. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.184 · Cited by 295
Yamagishi, S.-I., Maeda, S., Matsui, T., Ueda, S., Fukami, K., & Okuda, S. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.03.014 · Cited by 294
Intervention strategies to inhibit protein carbonylation by lipoxidation‐derived reactive carbonyls
Aldini, G., Dalle‐Donne, I., Facino, R. M., Milzani, A., & Carini, M. (2007) · Medicinal Research Reviews · doi:10.1002/med.20073 · Cited by 289
Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update
Bhattacharjee, N., Barma, S., Konwar, N., Dewanjee, S., & Manna, P. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.08.022 · Cited by 271
Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases
Reddy, V. P., & Beyaz, A. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.05.016 · Cited by 266
Williams, M. E., Bolton, W. K., Khalifah, R. G., Degenhardt, T. P., Schotzinger, R. J., & McGill, J. B. (2007) · American Journal of Nephrology · doi:10.1159/000108104 · Cited by 253
Self-citationUnlocking the biology of RAGE in diabetic microvascular complications
Manigrasso, M. B., Juranek, J., Ramasamy, R., & Schmidt, A. M. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.08.002 · Cited by 209
Nedić, O., Rattan, S. I. S., Grune, T., & Trougakos, I. P. (2013) · Free Radical Research · doi:10.3109/10715762.2013.806798 · Cited by 162
Glyoxalase 1 Modulation in Obesity and Diabetes
Rabbani, N., & Thornalley, P. J. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7424 · Cited by 102
Postprandial glucose spikes, an important contributor to cardiovascular disease in diabetes?
Hanssen, N. M. J., Kraakman, M. J., Flynn, M. C., Nagareddy, P. R., Schalkwijk, C. G., & Murphy, A. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.570553 · Cited by 90
“Unfortunately, aminoguanidine, the best known AGEinhibitor induced glomerulonephritis in a small subset of subjects at higher dosages (63), and its use in clinical studies has therefore been discontinued.”
BackgroundKidney, heart and brain: three organs targeted by ageing and glycation
Frimat, M., Daroux, M., Litke, R., Nevière, R., Tessier, F. J., & Boulanger, E. (2017) · Clinical Science · doi:10.1042/cs20160823 · Cited by 88
Metadata
- Authors
- Bolton, W. K., Cattran, D. C., Williams, M. E., Adler, S. G., Appel, G. B., Cartwright, K., Foiles, P. G., Freedman, B. I., Raskin, P., Ratner, R. E., Spinowitz, B. S., Whittier, F. C., Wuerth, J.-P., & for the ACTION I Investigator Group (Appendix), F.
- Venue
- American Journal of Nephrology
- Publisher
- S. Karger AG
- Published
- 2004
- Volume
- 24
- Issue
- 1
- Pages
- 32-40
- ISSN
- 0250-8095 (ISSN-L)
- 1421-9670
- OpenAlex
- W2019226618
- Cited by
- 461
- References
- 22
- FWCI
- 14.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.